Direct Thrombin Inhibitor Resistance and Possible Mechanisms

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Bivalirudin is a direct thrombin inhibitor used for anticoagulation.
• Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy.
• Standard dosing protocols for bivalirudin may not be sufficient in all clinical scenarios.

Purpose of the Study:

• To report cases requiring higher-than-usual bivalirudin doses for therapeutic anticoagulation.
• To investigate the time to achieve therapeutic anticoagulation and doses required.
• To explore potential resistance mechanisms to direct thrombin inhibitors.

Main Methods:

• Retrospective review of three patient cases requiring high-dose bivalirudin.
• Monitoring of anticoagulation using activated partial thromboplastin time (aPTT).
• Analysis of bivalirudin dosing, titration, and patient outcomes.

Main Results:

• Three patients required significantly higher bivalirudin doses (up to 1.8 mg/kg/h) to maintain therapeutic aPTT.
• Therapeutic anticoagulation was achieved after a median of 30.7 hours, with some cases taking up to 134 hours.
• Two patients showed unexpected increases in international normalized ratio (INR) with therapeutic aPTT.

Conclusions:

• Direct thrombin inhibitors like bivalirudin may be subject to resistance mechanisms.
• Clinical monitoring and potential dose adjustments are crucial for effective anticoagulation.
• Further studies are warranted to elucidate the mechanisms of resistance and optimize bivalirudin therapy.